| Mirtazapine Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Mirtazapine 15 mg | tablet | oral | 1.0 each | OTC |
| Mirtazapine 45 mg | tablet | oral | 1.0 each | OTC |
| Mirtazapine 7.5 mg | tablet | oral | 1.0 each | OTC |
| Mirtazapine 30 mg | tablet | oral | 1.0 each | OTC |
| Mirtazapine 30 mg | tablet, disintegrating | oral | 1.0 each | OTC |
| Mirtazapine 45 mg | tablet, disintegrating | oral | 1.0 each | OTC |
| Mirtazapine 15 mg | tablet, disintegrating | oral | 1.0 each | OTC |
Posted by andlen1 about 1 year ago
My husband was hospitalized at Fl Hospital April 11 – 16, 2008. He had severe stomach pain to the point he became suicidal. W...
Posted by dutchman over 2 years ago
I was taking Mirtazapine for about 18 months and despite it's reputation for not causing sexual side effects I experienced se...
Posted by lester.thompson over 3 years ago
I have a hard time getting up and walking after a nights rest or sitting for a while. I also have severe headaches and blurry...
Aripiprazole’s Receptor Pharmacology and Extrapyramidal Side Effects - Am J Psychiatry (subscription)
In contrast, a robust anti-akathisia effect of mianserin and mirtazapine (both with marked 5-HT 2A antagonism), comparable with propranolol (the drug of ...
Mon Mar 03 14:11:37 -0500 2008
Aripiprazole’s Receptor Pharmacology and Extrapyramidal Side Effects - Am J Psychiatry (subscription)
In contrast, a robust anti-akathisia effect of mianserin and mirtazapine (both with marked 5-HT 2A antagonism), comparable with propranolol (the drug of ...
Mon Mar 03 14:11:37 -0500 2008
Cognitive–behavioural therapy v. mirtazapine for chronic fatigue ... - British Journal of Psychiatry (subscription)
To examine the effect of a comprehensive cognitive–behavioural treatment (CCBT) programme compared with placebo-controlled mirtazapine medication in ...
Fri Feb 29 19:09:13 -0500 2008
mirtazapine - A synthetic derivative of piperazino-azepines, tetracyclic antidepressant Mirtazapine acts by an unknown mechanism that enhances central adrenergic and serotonergic transmission. Structurally unrelated to selective serotonin reuptake inhibitors, tricyclics, or monoamine oxidase inhibitors (MAOI), it also affects muscarinic transmission and has parasympatholytic properties. (NCI04)